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Abstract
Introduction Inhibitor of apoptosis (IAPs) proteins are a family
of proteins that can block apoptosis in normal cells and have
been suggested to cause resistance to apoptosis in cancer.
Overexpression of oncogenic receptor tyrosine kinases is
common in breast cancer; in particular 20% of all cases show
elevated Her2. Despite clinical success with the use of targeted
therapies, such as Trastuzumab, only up to 35% of Her2-
positive patients initially respond. We reasoned that IAP-
mediated apoptosis resistance might contribute to this
insensitivity to receptor tyrosine kinase therapy, in particular
ErbB antagonists. Here we examine the levels of IAPs in breast
cancer and evaluate whether targeting IAPs can enhance
apoptosis in response to growth factor receptor antagonists
and TRAIL.
Methods IAP levels were examined in a breast cancer cell line
panel and in patient samples. IAPs were inhibited using siRNA
or cell permeable mimetics of endogenous inhibitors. Cells were
then exposed to TRAIL, Trastuzumab, Lapatinib, or Gefitinib for
48 hours. Examining nuclear morphology and staining for
cleaved caspase 3 was used to score apoptosis. Proliferation
was examined by Ki67 staining.
Results Four members of the IAP family, Survivin, XIAP, cIAP1
and cIAP2, were all expressed to varying extents in breast
cancer cell lines or tumours. MDAMB468, BT474 and BT20
cells all expressed XIAP to varying extents. Depleting the cells of
XIAP overcame the intrinsic resistance of BT20 and
MDAMB468 cells to TRAIL. Moreover, siRNA-based depletion
of XIAP or use of a Smac mimetic to target multiple IAPs
increased apoptosis in response to the ErbB antagonists,
Trastuzumab, Lapatinib or Gefitinib in Her2-overexpressing
BT474 cells, or Gefitinib in EGFR-overexpressing MDAMB468
cells.
Conclusions The novel findings of this study are that multiple
IAPs are concomitantly expressed in breast cancers, and that, in
combination with clinically relevant Her2 treatments, IAP
antagonists promote apoptosis and reduce the cell turnover
index of breast cancers. We also show that combination therapy
of IAP antagonists with some pro-apoptotic agents (for example,
TRAIL) enhances apoptosis of breast cancer cells. In some
cases (for example, MDAMB468 cells), the enhanced apoptosis
is profound.
Introduction
One of the major hurdles in the treatment of breast cancer is
resistance to therapy, resulting in tumour recurrence and
patient mortality. A potential mechanism by which cancer cells
escape drug-induced cell death is their intrinsic, or indeed
acquired, resistance to apoptosis. Resistance may result from
a dysregulation of anti-apoptotic inhibitor of apoptosis (IAPs)
proteins or Bcl-2 proteins, which are therefore considered
novel therapeutic targets for cancer [1-3]. There has been little
work, however, to establish whether antagonists of endog-
enous anti-apoptotic proteins, such as IAPs, can improve the
efficacy of targeted therapies for breast cancer. In the present
article we conduct proof-of-principle studies to determine
whether IAPs contribute to the apoptosis resistance of breast
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cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)
and ErbB antagonists.
Apoptosis mainly occurs through one of two pathways, the
extrinsic pathway or the intrinsic pathway. The extrinsic path-
way is activated by death ligands such as TRAIL, while the
intrinsic pathway occurs in response to cell stresses such as
growth factor withdrawal or DNA damage. Following activa-
tion of either apoptotic pathway, the caspase family of pro-
teases execute cells through their proteolytic activity. IAPs can
in turn negatively regulate caspases, blocking apoptosis.
XIAP (BIRC4) is the most potent caspase inhibitor in the IAP
family: it binds to and inhibits active caspases 3, 7 and 9, and
additionally ubiquitinates them [4-7]. Two further IAPs, cIAP1
(BIRC2) and cIAP2 (BIRC3), also bind caspases but do not
directly inhibit them, instead inducing their proteasomal degra-
dation [8,9].
The IAPs themselves are controlled at several levels, including
the release of a pro-apoptotic factor – second mitochondrial
activator of caspases (Smac) – from the mitochondria during
apoptosis. Smac displaces caspases from XIAP, thereby pre-
venting the inhibitory function of XIAP and promoting caspase
activity [10]. The cIAPs achieve part of their anti-apoptotic
function by binding to and ubiquitinating Smac, freeing XIAP
to suppress caspase activity [8,9].
Since IAPs and their regulators act in a concerted manner dur-
ing apoptosis, their dysregulation can increase the threshold
for apoptosis in cancer, thereby contributing to disease pro-
gression [2]. For example, Survivin is normally only expressed
during mitosis in adult cells, but is dramatically upregulated in
many cancers leading to a poor prognosis for recurrence-free
survival [11-13]. Overexpression of the other IAP family mem-
bers in cancer also occurs but is not as clearcut as for Sur-
vivin. XIAP is ubiquitous in normal tissues, and is elevated in
some cancers including renal, acute myeloid leukaemia and
bladder cancer [14-16]. The correlation between elevated
XIAP levels and clinical outcome, however, is not straightfor-
ward since its overexpression correlates with disease severity
in acute myeloid leukaemia but not in lung cancer or prostate
cancer [17,18]. There are less data on cIAPs, although chro-
mosomal amplification of 11q21–q23, which encodes both
cIAP1 and cIAP2, is observed in oesophageal squamous cell
carcinomas and cIAP2-activating translocations can occur in
some B-cell lymphomas [1,19]. cIAP1 also has oncogenic
potential, as it has the ability to transform liver cells into
hepatomas in combination with the oncogene Yap [20].
The anti-apoptotic function of IAPs suggests that they are
attractive clinical targets (whether or not their levels are altered
in cancer). Antisense oligodeoxynucleotides directed against
XIAP and Survivin, and Smac mimetics targeting IAPs, are in
phase I and phase I/II clinical trials [21-23].
In breast cancer, most of the work on IAPs has focused on
Survivin. There are only a few reports examining the other
IAPs, and this is in a few cell lines [24-26]. Studies have
shown that inhibiting IAPs augments the apoptotic effect of
chemotherapeutics (for example, cisplatin and etoposide) [27-
29]. Few studies, however, have examined whether targeting
IAPs can improve the efficacy of newer targeted therapies
against oncogenic growth factor receptors in breast cancer
[30,31].
In the present study we examine IAP expression in 14 com-
monly used breast cancer cell lines compared with a nonma-
lignant control line. We show that inhibiting IAPs either using
siRNA directed against XIAP or using a Smac mimetic over-
comes the intrinsic resistance of some of the breast cancer
cell lines to both TRAIL and targeted therapies against ErbB
receptors. Inhibiting IAPs may be clinically relevant since the
IAP expression profile is altered in tumour biopsy samples.
Materials and methods
Antibodies
The following primary antibodies were used: cIAP2 and
Desmoplakin (Abcam, Cambridge, UK); monoclonal XIAP
(clone 2F1) and calnexin (Bioquote Ltd, York, UK); Ki67-FITC
(BD Transduction Labs, Franklin Lakes, NJ, USA); phospho-
Erk and oestrogen receptor alpha (Cell Signaling, Beverly, MA,
USA); Cytokeratin 8/18 (Progen, Heidelberg, Germany); Sur-
vivin (Novus Biologicals, Littleton, CO, USA); cleaved caspase
3 (R&D Systems, Abingdon, UK); Erk, mouse monoclonal epi-
dermal growth factor receptor (EGFR) (R1) and rabbit polyclo-
nal EGFR (Santa Cruz, Santa Cruz, CA, USA); and Her2
(Upstate, Millipore, MA, USA). Anti-cIAP1 was a generous gift
from J Silke [32].
Cell culture
HS578T cells, MDAMB468 cells, CAL51B cells,
MDAMB231 cells, SKBR3 cells, MCF7 cells, Zr-75-1 cells,
BT474 cells, BT20 cells and T47D cells were all grown in
DMEM supplemented with 10% FCS, 2 mM glutamine, peni-
cillin-streptomycin. PMC42 cells were grown in RPMI with
10% FCS, 2 mM glutamine, penicillin-streptomycin. The
receptor status of the cell lines was confirmed by western blot-
ting (data not shown).
The MCF10 progression panel cells (from K Brennan and orig-
inally from the Karmanos Cancer Institute, Detroit, MI, USA)
were grown in DMEM/F12 media supplemented with 5%
horse serum, 2 mM glutamine, penicillin-streptomycin, with
additional 5 μg/ml hydrocortisone, 10 μg/ml insulin, and 20
ng/ml epidermal growth factor for the MCF10a cells,
MCF10neoT cells, and MCF10AT1 cells.
Tumour samples
Approval to remove normal and tumorigenic human breast tis-
sues during reduction mammoplasty and from pathologic sam-Available online http://breast-cancer-research.com/content/11/3/R41
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ples, respectively, was obtained from the Manchester Local
Research Ethics Committees. Written informed consent was
obtained from the patients before surgery.
The receptor status of the tumour samples was determined
clinically. Frozen sections were diced with a clean razor blade
before lysis in RIPA buffer (150 mM NaCl, 50 mM Tris, pH 7.4,
5 mM ethylenediamine tetraacetic acid, 1% NP-40, 1% deox-
ycholate, 10 mM NaF, 1 mM Na3VO4, 1× Protease Inhibitor
Cocktail (Calbiochem, San Diego, CA, USA)) and protein
expression was analysed by immunoblotting.
Cell lysis and immunoblotting
Cells were routinely lysed at 80% confluency in RIPA buffer.
Proteins were separated by SDS-PAGE and transferred to
nitrocellulose membranes, and were subsequently detected
using the relevant primary antibody and appropriate secondary
antibody (1:10,000). Secondary antibody detection was per-
formed with either peroxidase-conjugated antibodies from
Jackson Immunoresearch (West Grove, PA, USA) and Pierce
SuperSignal West Pico Chemiluminescent Substrate (Rock-
ford, IL, USA), or IR-dye™-800 (Rockland Immunochemicals,
Gilbertsville, PA, USA) and AlexaFluor-680-conjugated anti-
bodies (Invitrogen, Carlsbad, CA, USA) for Odyssey™ Infrared
Imaging (Li-Cor, Lincoln, NE, USA). Dr Stephen P Ethier gen-
erously provided SUM cell RIPA lysates from the Karmanos
Institute.
siRNA transfection
Three siRNA oligonucleotides directed against each of XIAP
and Survivin (Ambion) and a scrambled negative control
siRNA (mock) were tested for effectiveness of protein knock-
down. Transfection was performed with Lipofectamine 2000
(Invitrogen), according to the manufacturer's instructions.
Transfections with a Cy3-conjugated scrambled negative con-
trol siRNA showed ~80% transfection efficiency in all cell lines
used.
Drug treatment
Cells were treated with TRAIL (10 ng/ml; Alexis Biochemicals,
Grunberg, Germany), Trastuzumab (Herceptin®, 100 μg/ml),
Lapatinib (Tykerb, GW572016, 100 nM), Gefitinib (Iressa, 10
μM) or Smac mimetic (10 nM) (generously provided by X
Wang, University of Texas Southwestern Medical Centre at
Dallas, TX, USA) for 48 hours when examining effects on
apoptosis and proliferation. When examining the effects of the
drugs on Erk signalling, cells were serum starved for a mini-
mum of 4 hours prior to addition of the drugs for an additional
24 hours. Cells were then stimulated with epidermal growth
factor (100 ng/ml) for 15 minutes at 37°C and lysed.
Apoptosis and proliferation measurements
Cells were spun onto polysine®-coated slides, fixed in 4% for-
maldehyde and permeabilised in 0.2% Triton X-100. Nonspe-
cific binding sites were blocked in 10% goat serum in PBS
prior to staining for cleaved caspase 3 and the proliferation
marker Ki67. Cells were co-stained with 4',6 diamidino-2-phe-
nylindole (DAPI) and were viewed on an Axioplan2 micro-
scope (Carl Zeiss MicroImaging Inc., Jena, Germany).
Apoptosis was scored by examining nuclear morphology or
caspase 3 staining. Counts were performed blind to prevent
any bias, and at least 500 cells over two or more fields of view
were counted for each sample. The cell turnover index (CTI)
was calculated by dividing the percentage of proliferation by
the percentage of apoptosis [33].
Statistical analysis
A two-way analysis of variance was used. P < 0.05 indicated
significance. Results are presented as the mean ± standard
error of the mean from at least three experiments, unless
stated otherwise.
Results
Inhibitor of apoptosis expression in common breast 
cancer cell lines
We examined the expression profile of the IAP family in a panel
of commonly used breast cancer cell lines, together with the
nonmalignant MCF10a cell line.
XIAP was ubiquitously expressed, but its levels varied across
the panel (Figure 1a). Compared with MCF10a cells, XIAP
was higher in only MDAMB468 and T47D cells. In contrast,
cIAP1 was not detected in MCF10a cells but was markedly
upregulated in the Sum 225, Sum 190 and BT20 cells com-
pared with the MCF10a nonmalignant cell line (Figure 1b). On
the other hand, cIAP2 was frequently expressed at lower levels
in the cancer cell lines than in MCF10a cells. cIAP2 could be
detected, however, in the Sum 225, Sum 190, and Sum 44
cell lines. Longer exposure times also showed cIAP2 was
found in the MDAMB468, Zr-75-1 and T47D cell lines (see
Additional data file 1).
In contrast to the variable expression of XIAP, Survivin was ele-
vated in about one-half of the cell lines examined in the present
study while none was detected in the control MCF10a cell
line. Marked increases in Survivin were seen in MDAMB468
cells, CAL51 cells, MDAMB231 cells, SKBR3 cells, PMC42
cells and BT474 cells compared with expression in MCF10a
cells (Figure 1c).
Since the cell lines used above are from disparate sources, we
also examined IAP levels in a separate panel of isogenic breast
cell lines that shows increasing severity of tumour phenotype.
This is the MCF10 progression panel, which includes the nor-
mal immortalised MCF10a cells, Ha-Ras transformed
MCF10neoT cells, premalignant MCF10AT1 cells, a cloned
xenograft lesion of MCF10AT1 cells (MCF10DCIS.com), and
malignant variants that form invasive tumours with varying
degrees of differentiation in xenografts (MCF10CA1, h, d, and
a) [34,35].Breast Cancer Research    Vol 11 No 3    Foster et al.
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Figure 1
Inhibitor of apoptosis levels in breast cancer Inhibitor of apoptosis levels in breast cancer. Inhibitor of apoptosis (IAP) expression in a panel of normal and breast-cancer-derived cell lines was 
examined by immunoblotting with antibodies for (a) XIAP, (b) cIAP1 and cIAP2 (blotted sequentially) and (c) Survivin. Survivin and XIAP were 
detected on the same blot, which was stripped and reprobed for calnexin. (d) IAP expression was also determined in the MCF10 progression panel: 
(i) cIAP2, XIAP and Survivin and (ii) cIAP1. Representative blots from four experiments for the cell lines are shown. The receptor status of each cell 
line, determined by western blotting, is shown; there is no correlation with IAP expression. ER, oestrogen receptor; EGFR, epidermal growth factor 
receptor.
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In comparison with the parental MCF10a cells, Survivin, XIAP
and cIAP1 were upregulated in all the transformed cells (Fig-
ure 1di, dii). cIAP2 levels appeared to decrease as the cell
lines became more malignant. Interestingly, elevated Survivin,
XIAP and cIAP1 levels were detected in cells corresponding
to the early stages of breast cancer progression, in atypias
(MCF10neoT and MCF10AT1 cells) and in MCF10DCIS-like
cells.
Knockdown of XIAP sensitises cells to TRAIL
Since XIAP is the most potent caspase inhibitor in the IAP fam-
ily, we determined whether it contributed to the apoptotic
resistance of breast cancer cells using RNAi. Each of three
separate siRNAs targeting XIAP diminished its protein expres-
sion, and the sequence chosen for further studies reduced
XIAP levels by greater than 80% in all cell lines used (Figure
2ai, bi). XIAP knockdown did not result in any significant
changes in levels of the closely related cIAPs or Survivin (data
not shown). The data obtained in the subsequent experiments
were confirmed using a second siRNA sequence to rule out
off-target effects (see Additional data file 2).
To show that XIAP antagonism augments drug-induced apop-
tosis in breast cancer cells, we initially examined its effects in
conjunction with TRAIL [26,36]. Currently in clinical trials for
colon cancer, TRAIL initiates apoptosis through death recep-
tor (DR4 or DR5)-induced activation of caspase 8. This path-
way culminates in the activation of caspases 3 and 7, which
are in turn inhibited by XIAP. The combination of TRAIL and
XIAP antagonism was investigated in MDAMB468 cells,
which express higher levels of XIAP than MCF10a cells, as
well as BT20 and BT474 cells, which have similar or lower lev-
els of XIAP (Figure 1a).
BT20 and MDAMB468 cells were insensitive to TRAIL (10 ng/
ml), as shown by the lack of TRAIL-induced apoptosis in mock-
transfected cells (Figure 2aii, compare black and grey col-
umns in mock samples; the apoptosis data presented were
determined by examining nuclear morphology, but in all cases
similar results were obtained when cells were stained for
cleaved caspase 3). Knockdown of XIAP significantly
increased TRAIL-induced apoptosis in BT20 and MDAMB468
cells by 2.3-fold and 2.5-fold, respectively (Figure 2aii, com-
pare grey columns between mock and siRNA transfected sam-
ples for each cell line).
In BT474 cells, which were initially sensitive to TRAIL-induced
apoptosis (Figure 2bii, compare black and grey columns in
mock transfected samples), knockdown of XIAP also resulted
in a significant increase in TRAIL-induced apoptosis (Figure
2bii, compare grey columns between mock and XIAP siRNA
samples). As well as targeting XIAP alone, we used a Smac
mimetic (compound 3) that targets multiple IAPs by preventing
the XIAP-mediated suppression of caspase activity and
depleting the cells of cIAP1 and cIAP2 [37,38]. Smac mimetic
(10 nM, 48 hours) resulted in complete depletion of cIAP1,
and in a slight decrease in XIAP levels (Figure 2bi), but had no
significant apoptotic effect on any of the cell lines in the
absence of an apoptosis inducer (Figure 2bii, compare black
columns (nt) between no inhibitor samples (con) and Smac
mimetic samples). However, the Smac mimetic potentiated
TRAIL-induced apoptosis compared with TRAIL treatment
alone (1.7-fold), confirming the cooperative effect of IAP
antagonists with TRAIL (Figure 2bii, compare grey columns for
no inhibitor samples (con) versus Smac mimetic-treated sam-
ples).
In MDAMB468 cells, Smac induced depletion of cIAP1 and
also decreased levels of cIAP2 (Figure 2ci). The effect of the
Smac mimetic on MDAMB468 cells was more pronounced,
causing a 5.8-fold increase in TRAIL-induced apoptosis (Fig-
ure 2c, compare grey columns in no inhibitor (con) samples
versus Smac mimetic-treated samples). Since a much greater
effect was seen with the Smac mimetic than with siRNA XIAP
(compare Figures 2c and 2aii), this suggests that the cIAPs
may play a key role in the resistance to TRAIL seen in
MDAMB468 cells. Interestingly, the apoptotic effect of the
Smac mimetic and TRAIL was specific to cancer cell lines as
neither Smac nor TRAIL, alone or in combination, had any
effect on the nonmalignant MCF10a cell line (see Additional
data file 3).
Regardless of the levels of XIAP in the cell lines, therefore,
inhibiting XIAP either overcame the resistance to TRAIL (BT20
and MDAMB468 cells) or showed a synergistic increase in the
apoptotic response to TRAIL (BT474 cells). Moreover, in
MDAMB468 cells, targeting multiple IAPs in combination with
TRAIL treatment produced a profound increase in apoptosis
compared with targeting XIAP alone.
Targeting XIAP sensitises cells to ErbB antagonists
A current strategy to treat cancer is via targeted drugs that
antagonise oncogenically activated growth factor receptors.
Many breast cancers overexpress Her2 (20% of all cases) and
the EGFR. Targeting these receptors, to which the cancer
cells have become addicted for survival, should block prolifer-
ation and either induce or sensitise the cells to apoptosis via
the intrinsic pathway, thus providing the rational for using
EGFR and Her2 in breast cancer therapy. Trastuzumab is a
humanised monoclonal antibody, which inhibits Her2 and
decreases proliferation in Her2-overexpressing cells such as
BT474 [39]. Lapatinib is a dual kinase inhibitor of EGFR and
Her2, while Gefitinib is a selective EGFR kinase inhibitor (but
at higher concentrations, Gefitinib inhibits both the EGFR and
Her2) [40,41].
To determine whether targeting IAPs in combination with
these ErbB antagonists increased apoptosis, we used the
Her2-overexpressing BT474 cells, which are predicted to be
sensitive to inhibition by all three antagonists, and used theBreast Cancer Research    Vol 11 No 3    Foster et al.
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Figure 2
Inhibitor of apoptosis suppression sensitises cells to TRAIL-induced apoptosis Inhibitor of apoptosis suppression sensitises cells to TRAIL-induced apoptosis. (a) BT20 and MDAMB468 cells were transfected with siRNA target-
ing XIAP, and 24 hours later cells were treated with TNF-related apoptosis-inducing ligand (TRAIL) (10 ng/ml) for 48 hours. Cells were then either (i) 
analysed by western blotting to confirm knockdown or (ii) cytospun and scored for apoptosis by staining for nuclear morphology. Data presented as 
fold changes in apoptosis (mean ± standard error of the mean (SEM)) from at least three independent experiments. (b) BT474 cells were either 
transfected with siRNA targeting XIAP and drug treated as above or treated with the Smac mimetic (10 nM) for 2 hours prior to TRAIL (10 ng/ml) 
addition for 48 hours: (i) knockdown was confirmed by western blotting (cIAP1 only, as cIAP2 was not detected in BT474 cells), and (ii) apoptosis 
was scored by examining nuclear morphology. Data presented as fold changes in apoptosis (mean ± SEM) from at least three independent experi-
ments. (c) Effect of the Smac mimetic on MDAMB468 cells, examined as for BT474 cells in (b). Data presented as mean ± SEM from at least three 
experiments. nt, not treated; con, no IAP inhibitor.Available online http://breast-cancer-research.com/content/11/3/R41
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EGFR-overexpressing MDAMB468 cells, which should be
sensitive to Gefitinib and Lapatinib but not Trastuzumab. Con-
sistent with these ErbB receptor profiles, all three drugs signif-
icantly blocked proliferation in BT474 cells, and only Lapatinib
and Gefitinib inhibited proliferation in the MDAMB468 cells
(Figure 3a). We found that Lapatinib and Gefitinib inhibited
Erk activation downstream of the EGFR, in BT474 cells,
although Trastuzumab (as previously reported) was unable to
do so (Figure 3b) [42]. MDAMB468 cells showed resistance
to both Gefitinib and Lapatinib at the level of Erk phosphoryla-
tion [41,43].
There is evidence that, in addition to blocking proliferation,
these ErbB antagonists sensitise cells to apoptosis [42,44-
46]. For example, Trastuzumab promotes apoptosis of breast
cancer cells in vivo, and we have previously shown that Gefit-
inib induces apoptosis of normal breast epithelia through the
intrinsic apoptosis pathway [46-49]. In BT474 and
MDAMB468 cells, however, neither Trastuzumab, Lapatinib
nor Gefitinib significantly elevated apoptosis above back-
ground (Figure 4a, b, c, compare black columns). We there-
fore reasoned that downregulating IAPs might sensitise the
cells to undergo apoptosis in response to ErbB antagonists.
In control experiments XIAP knockdown had no significant
effect on basal rates of apoptosis in any of the cell lines (Figure
4a, b, compare grey with black columns in no inhibitor sam-
ples). In addition, depleting XIAP by siRNA had no effect on
Figure 3
ErbB antagonists inhibit growth factor-induced proliferation and signalling ErbB antagonists inhibit growth factor-induced proliferation and signalling. (a) The anti-proliferative effect of the ErbB antagonists was confirmed in 
BT474 and MDAMB468 cells, using Ki67 staining as a proliferation marker (48 hours post drug treatment). Data presented as mean ± standard 
error of the mean from at least three experiments. (b) Cells were serum-starved for 4 hours prior to the addition of vehicle only (con), Trastuzumab 
(100 μg/ml), Lapatinib (100 nM) or Gefitinib (10 μM) for 24 hours. Cells were stimulated with epidermal growth factor (EGF) (100 ng/ml) for 15 min-
utes at 37°C. Activation of Erk was detected by immunoblotting (IB).
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the proliferation of any of the lines either in the presence or
absence of the ErbB therapies (data not shown). XIAP deple-
tion did, however, sensitise the cells to ErbB antagonist-
induced apoptosis. This was most apparent in the ErbB2-over-
expressing BT474 cells, where XIAP knockdown induced sig-
nificant increases in response to Trastuzumab, Lapatinib and
Gefitinib (4.7-fold, 1.9-fold, and 1.8-fold, respectively) (Figure
4a, compare grey with black columns in each drug-treated
sample). In the EGFR-only overexpressing MDAMB468 cells,
XIAP depletion significantly increased apoptosis in response
to Gefitinib (1.7-fold) (Figure 4b, compare grey with black col-
umns in each drug-treated sample).
We also examined whether the Smac mimetic enhanced the
apoptotic effect of the ErbB antagonists. In the BT474 cell
line, similar data to that seen with XIAP depletion were
obtained with the Smac mimetic, which caused statistically
significant increases in apoptosis induced by Trastuzumab,
Lapatinib and Gefitinib (1.5-fold, 2.6-fold, and 1.5-fold,
respectively) (Figure 4c, compare grey with black columns in
each drug-treated sample).
The apoptotic response of some breast cancer cell lines to tar-
geted therapies is therefore enhanced either by siRNA-medi-
ated depletion of XIAP or by targeting multiple IAPs with a
Smac mimetic. Although the overall amounts of apoptosis are
modest following combined IAP suppression and ErbB antag-
onism, they are still relevant. Indeed, even small increases in
apoptosis can have large effects on the CTI. The CTI meas-
ures the turnover of cells in a tumour, accounting for altera-
tions in both proliferation and apoptosis. In BT474 cells,
Trastuzumab, Lapatinib or Gefitinib induced significant
decreases in the CTI of 2.5-fold, 5.5-fold, and 9.2-fold, respec-
tively (Figure 4d, compare black columns). Importantly, the CTI
was decreased by a further fivefold, fourfold, and 2.4-fold,
respectively, upon depletion of XIAP (Figure 4d, compare grey
with black columns), resulting in combined decreases over
untreated controls of 12.7-fold, 23-fold, and 22.4-fold, respec-
Figure 4
Targeting inhibitors of apoptosis increases sensitivity to ErbB antagonists Targeting inhibitors of apoptosis increases sensitivity to ErbB antagonists. (a) BT474 cells and (b) MDAMB468 cells were transfected with siRNA 
targeting XIAP, and 24 hours later were treated with Trastuzumab (100 μg/ml), Lapatinib (100 nM), or Gefitinib (10 μM) for 48 hours. Apoptosis was 
scored, by examining nuclear morphology. Data presented as fold changes in apoptosis (mean ± standard error of the mean (SEM)) from at least 
three experiments. (c) BT474 cells were pretreated with the Smac mimetic for 2 hours before addition of Trastuzumab (100 μg/ml), Lapatinib (100 
nM), or Gefitinib (10 μM). Cells were examined for nuclear morphology 48 hours later. Data presented as fold changes (mean ± SEM) from at least 
three experiments. (d) Cell turnover indexes (CTIs) for ErbB antagonist-treated BT474 cells in the presence or absence of XIAP depletion. Data pre-
sented as mean ± SEM from at least three experiments. *P values indicating significance. nt, not treated; con, no ErbB antagonist.Available online http://breast-cancer-research.com/content/11/3/R41
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tively. As with XIAP knockdown, treatment with the Smac
mimetic also reduced the CTI compared with drug treatment
alone (data not shown).
Together, the increase in drug-induced apoptosis and the cor-
responding decrease in the CTI caused by IAP inhibition in
BT474 and MDAMB468 cells demonstrate that IAPs can
mediate resistance to ErbB antagonist-induced apoptosis in
breast cancer cell lines. Targeting IAPs may therefore be
important for use in combination therapies in the clinic.
Survivin, and XIAP are upregulated in breast cancer 
biopsies
To examine IAP levels in breast cancer, we examined their
expression at the protein level in biopsies of 11 or 12 breast
tumours. Tumour samples were chosen to represent the major
breast cancer subtypes: oestrogen receptor-positive and pro-
gesterone receptor-positive, oestrogen receptor-positive and
progesterone receptor-negative, oestrogen receptor/proges-
terone receptor/ErbB2-positive, and oestrogen receptor-neg-
ative and progesterone receptor-negative (see Additional data
file 4). The IAP levels were compared with those in normal tis-
sue samples obtained from reduction mammoplasties.
XIAP was not detected in the normal tissue samples examined,
and by comparison was elevated in eight out of 11 tumours
(numbers 3512, 2963, 2075, 895, 1156, 1223, 1952 and
2692) (Figure 5a). cIAP1, however, was present in both nor-
mal and tumour tissue samples at relatively equal levels (Figure
5b). cIAP2 appeared to be at higher levels in the normal breast
tissue samples compared with in the breast tumour samples
(Figure 5c), mirroring what was seen in the cell line data. Sur-
vivin was upregulated in five out of the 12 tumour samples
(numbers 895, 1849, 1223, 2692 and 3277), whereas it was
absent in the blots of normal tissue samples (Figure 5c).
These data show that despite the variability in XIAP levels in
the cell line panel, some patient samples show a marked
upregulation of IAPs – and in fact multiple IAPs are upregu-
lated in some cases (numbers 895, 1156). Also, since the pat-
tern of IAP upregulation varies between tumour samples, any
IAP-based therapy is going to need to be targeted at the cor-
rect IAP – and in some cases multiple IAPs – in a patient-spe-
cific manner.
Discussion
The most important finding of the present study is that IAP
antagonists in combination with clinically relevant ErbB family
therapeutics promote apoptosis and dramatically reduce the
CTI of breast cancers. We would therefore argue that,
together with appropriate biomarkers, treating certain patients
with IAP and ErbB antagonists together could be of clinical
value.
We also present a note of caution, however, because some
cell lines such as BT20 cells were responsive to treatment
with IAP antagonists combined with TRAIL, but not the ErbB
antagonists (data not shown).
Inhibitor of apoptosis expression in breast cancer cell 
lines and biopsy samples
The upregulation of Survivin both in the breast cancer biopsy
and in cell line panels is consistent with studies that have
shown 71% of breast cancers were positive for Survivin, while
the surrounding tissue was negative [50]. Survivin overexpres-
sion in tumours also seemed to correlate with Her2 overex-
pression, consistent with previous studies [51]. Of crucial
importance in Survivin overexpression is its localisation,
because nuclear Survivin indicates a good prognosis for recur-
rence-free survival in breast cancer, while cytoplasmic Survivin
has a poorer outcome [13,50,52,53]. We have previously
shown that MDAMB468 cells express both nuclear and cyto-
plasmic Survivin, thereby reflecting what occurs in vivo, and
that cytoplasmic Survivin has an anti-apoptotic role [54].
Despite a number of anti-Survivin therapies currently showing
promise in clinical trails, however, targeting of Survivin with
siRNA in the BT474 cells did not elevate their apoptotic sen-
sitivity to TRAIL or to the ErbB antagonists Lapatinib or Gefit-
inib (see Additional data file 5).
XIAP is the most potent caspase inhibitor of all of the IAPs, and
blocks both the intrinsic and extrinsic apoptosis pathways by
binding to caspases 3, 7 and 9. Currently there are surpris-
ingly few studies on XIAP in breast cancer, and these few have
focused on a limited number of cell lines; to our knowledge,
only one other study has examined its in vivo expression in
comparison with normal breast, where XIAP positivity corre-
lated with tumour grade [2,25]. As with previous studies in the
breast cancer cell lines and in the National Cancer Institute
(NCI) panel of tumour cell lines, we found that XIAP expression
was variable [16,26]. This variability possibly reflects the mul-
tiple mechanisms by which XIAP can be regulated, all of which
or some of which may be altered in cancer. Despite this varia-
bility in the cell line panel, XIAP was more markedly upregu-
lated in a subset of the breast tumour samples compared with
normal tissue.
In the case of cIAP1, there was a marked upregulation in the
cancer cell lines compared with MCF10a cells. No such
upregulation was seen, however, in the tumour panel. The
present study is the first that has examined cIAP1 protein in
breast tumour biopsies and compared its expression between
normal breast epithelia and breast cancer samples or cell
lines. Interestingly, we found that cIAP2 was lower in the can-
cer cell lines versus normal cell lines (confirmed with a second
anti-cIAP2 antibody) and in the tumour tissue versus normal
tissue samples. Future studies involving greater patient num-
bers with matched cancer and normal tissue samples areBreast Cancer Research    Vol 11 No 3    Foster et al.
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required to confirm the variation in cIAP1 and the possible
downregulation of cIAP2 in invasive carcinomas.
Overall, these data demonstrate that multiple IAPs are
expressed in breast cancer and therefore are potentially
responsible for apoptotic resistance. IAPs, in particular XIAP
and cIAPs, are therefore potential targets for lowering the
apoptotic threshold of breast cancers, making them more sen-
sitive to therapeutic drugs. We confirmed this hypothesis by
examining TRAIL-induced apoptosis in the presence or
absence of an XIAP siRNA or a Smac mimetic. Importantly,
this had a major effect in one cell line – the MDAMB468 cells.
The Smac mimetic has also been shown to substantially
increase TRAIL-induced apoptosis in the MDAMB231 cell line
[26]. Interestingly both the MDAMB468 and MDAMB231
cells are triple-negative (oestrogen receptor/progesterone
receptor/ErbB2-negative) cell lines. In BT474 cells and BT20
cells, which did not appear to have elevated levels of XIAP,
inhibition of XIAP also increased TRAIL-induced apoptosis,
suggesting that XIAP does not need to be overexpressed for
the Smac mimetic to be of use. Of potential clinical impor-
tance, neither TRAIL nor the Smac mimetic had any effect in
the MCF10a cell line.
Inhibitors of apoptosis and ErbB antagonists
Only a few studies have looked at combining XIAP inhibitors
with targeted therapies to growth factor receptors. In human
glioblastoma multiforme, combining the platelet-derived
growth factor receptor antagonist Imatinib with a Smac
mimetic significantly increased cell death compared with Imat-
inib treatment alone [55]. In breast cancer, Smac mimetics
have been shown to increase the apoptotic effect of Tamoxifen
Figure 5
Inhibitor of apoptosis levels in patient samples Inhibitor of apoptosis levels in patient samples. Inhibitor of apoptosis (IAP) levels in breast cancer biopsy samples and in samples of normal breast 
(N1 to N3) from reduction mammoplasties were examined by immunoblotting with the relevant antibodies. (a) XIAP was detected using enhanced 
chemiluminescence, blots were then stripped and reprobed for cytokeratin 18 (CK18). (b) cIAP1 and (c) cIAP2 and Survivin were detected using 
the Li-Cor Odyssey™ system. Blots were simultaneously probed for Desmoplakin. Prognostic indicators were determined in the clinic. ER, oestrogen 
receptor; EGFR, epidermal growth factor receptor; PR, progesterone receptor; +, positive; -, negative; nd, not determined.Available online http://breast-cancer-research.com/content/11/3/R41
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in oestrogen receptor-overexpressing cell lines [30]. In inflam-
matory breast cancer, Trastuzumab treatment was shown to
induce an upregulation of XIAP expression. When XIAP was
targeted in these inflammatory breast cancer cell lines, a
greater decrease in cell viability was observed in combination
with Trastuzumab than with Trastuzumab treatment alone [31].
We have studied the combination of IAP targeting and growth
factor receptor inhibition in breast cancer cell lines, where
overexpression of the EGFR or Her2 is common. In these cell
lines, treatment with the growth factor receptor antagonists
did not induce changes in IAP expression levels (data not
shown). We found that IAP inhibition alone did not affect the
basal rates of apoptosis. In combination with a targeted ther-
apy, however, IAP inhibition resulted in increased rates of
apoptosis and substantially reduced the CTI. This indicates
that IAP inhibition alone has no detrimental effect on cells, but
would enhance apoptosis in cancer cells targeted by the
breast-cancer-specific therapeutics. We therefore suggest
that inhibiting IAPs may be a valuable adjunct to other thera-
pies in a clinical setting.
Further research still needs to be done in order to determine
what else, other than IAPs, might be contributing to the apop-
totic resistance of breast cancer cells. Such factors possibly
include members of the Bcl-2 family, which are upregulated in
some breast cancers.
Conclusions
The combination of IAP antagonists with drugs that target
ErbB receptors promotes apoptosis and dramatically reduces
the cell turnover index of some breast cancer cell lines. We
suggest that treating certain patients with IAP and ErbB antag-
onists together could be of clinical benefit.
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Smac mimetic on TRAIL-induced apoptosis in 
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